Clinical Trial Applications - Stopped: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 5, showing 10 Applications out of 44 total, starting on record 21, ending on 30

# Protocol No Study Title Investigator(s) & Site(s) Date Stopped

21.

ECCT/23/01/04   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Lucas Tina Otieno
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
4. Kenyatta National Hospital (Nairobi City county)
5. Ahero Clinical Trials Unit, (Kisumu county)
6. KEMRI CCR – BUTERE SITE (Kakamega county)
 
Not recorded View

22.

ECCT/20/11/05   HOPE Kids 2
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. KEMRI/CRDR Clinical Research Annex (Nairobi City county)
3. Strathmore University Medical Centre (Nairobi City county)
4. KEMRI/CRDR Siaya (Siaya county)
 
Not recorded View

23.

ECCT/23/10/06   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Godfrey Allan Otieno
2. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI-Kondele Children’s Hospital (Kisumu county)
2. KEMRI CRDR Clinical Research Annex (Nairobi City county)
 
Not recorded View

24.

ECCT/23/12/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Benson Ochieng Singa
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
 
Not recorded View

25.

ECCT/24/05/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Walter Otieno
Site(s) in Kenya
1. KEMRI - Kombewa Clinical Research Centre (Kisumu county)
 
Not recorded View

26.

ECCT/23/01/07   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. KEMRI/USAMRD (Kericho county)
3. Kenya Medical Research Institute/USAMRU (Kisumu county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

27.

ECCT/23/03/08   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Deborah Chepngeno Lang\'at Chepngeno Lang\'at
Site(s) in Kenya
1. KEMRI/USAMRD (Kericho county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. Kenya Medical Research Institute/USAMRU (Kisumu county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI/ CDC (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

28.

ECCT/23/02/07   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Maricianah Onono Onono
Site(s) in Kenya
1. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

29.

ECCT/23/04/06   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr. Walter Otieno Otieno
Site(s) in Kenya
1. Kenya Medical Research Institute/USAMRU (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
5. KEMRI CRDR - Clinical Research Nairobi (Siaya county)
6. KEMRI/ CDC (Kisumu county)
7. KEMRI (Kisumu county)
8. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
Not recorded View

30.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
Not recorded View